ADC Therapeutics shares are trading lower after the company paused enrollment in Phase 2 LOTIS-9 trial of Zynlonta and rituximab in unfit or frail patients with previously untreated diffuse large b-cell lymphoma.
Portfolio Pulse from Benzinga Newsdesk
ADC Therapeutics has paused enrollment in its Phase 2 LOTIS-9 trial of Zynlonta and rituximab in unfit or frail patients with previously untreated diffuse large b-cell lymphoma. This has led to a decrease in the company's share price.
July 11, 2023 | 12:46 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
ADC Therapeutics' decision to pause enrollment in its Phase 2 LOTIS-9 trial has negatively impacted its share price.
The pause in the trial enrollment indicates potential issues with the trial or the drug, which can negatively impact investor confidence in the company's future prospects. This can lead to a decrease in demand for the company's shares, resulting in a drop in the share price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100